Nuvation Bio grants 748,130 stock options to officer

Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options.

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options. These options were acquired as a derivative security award and increase his directly held option position to 748,130 options.

According to the terms, the option vests as to 25% on the one-year anniversary of February 27, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on Hanley’s continuous service on each vesting date.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 1 txn

Insider Hanley David C.

Role CHIEF TECHNICAL OPERATIONS

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct)

Footnotes (1)

1. F1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) report for David C. Hanley?

Nuvation Bio reported that David C. Hanley, its Chief Technical Operations officer, acquired a grant of 748,130 stock options. This award is reported as a derivative security and represents his total directly held options following the transaction, according to the Form 4 details and footnotes.

How many stock options were granted to Nuvation Bio (NUVB) executive David C. Hanley?

David C. Hanley was granted 748,130 stock options in a single derivative transaction. The Form 4 indicates this entire amount as both the transaction size and his total stock options directly held after the grant, reflecting a new equity award to the executive.

What is the vesting schedule for David C. Hanley’s 748,130 Nuvation Bio (NUVB) stock options?

The option vests 25% on the one-year anniversary of February 27, 2026. The remaining 75% then vests in equal monthly installments over the following 36 months, provided Hanley continues to serve the company on each applicable vesting date, as specified in the footnote.

Does the Nuvation Bio (NUVB) Form 4 show David C. Hanley owning options directly or indirectly?

The Form 4 indicates David C. Hanley’s ownership as direct, marked with ownership code “D.” There is no footnote shifting voting or investment authority to another entity, so the 748,130 stock options are reported as directly held by the reporting person after the grant.

What transaction code is used for David C. Hanley’s Nuvation Bio (NUVB) option grant?

The filing uses transaction code “A,” which the data describes as a grant, award, or other acquisition. This code indicates the 748,130 stock options were acquired as an equity award rather than through an open-market purchase or sale, according to the Form 4 transaction description.

What role does David C. Hanley hold at Nuvation Bio (NUVB) in this Form 4 filing?

David C. Hanley is identified as an officer of Nuvation Bio with the title “Chief Technical Operations.” The Form 4 reflects his status as a company officer and reports the grant of 748,130 stock options tied to his ongoing service to the organization.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:52 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanley David C.

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPERATIONS

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(1)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.